自身免疫性风湿病免疫抑制成人接种新冠疫苗(COVIAAD):Moderna Spikevax 基础免疫系列后 12 个月的安全性、免疫原性与抗体持久性
COVIAAD 是一项为期 12 个月的前瞻性、非随机、开放标签、对照试验,纳入类风湿关节炎(RA,n=131)、接受吗替麦考酚酯(MMF)的系统性红斑狼疮(SLE,n=23)、泼尼松≥10 mg/日的其他风湿病(n=8)患者及年龄/性别匹配的健康对照(HC,n=58)。Moderna Spikevax 基础免疫系列安全性良好,但 RA 和 SLE 患者接种后免疫原性及中和抗体较 HC 降低,MMF、RA 年龄>65 岁及利妥昔单抗与疫苗诱导保护降低相关。
要点
- Moderna Spikevax 基础免疫系列在 RA、SLE 及其他风湿病患者中安全性良好,未报告疫苗相关严重不良事件。
- RA 和 SLE 患者接种后免疫原性及中和抗体较健康对照降低,差异的置信区间均排除无效值。
- RA 中年龄>65 岁(OR 0.3,95%CI 0.1 至 0.8)和利妥昔单抗治疗(OR 0.003,95%CI 0.001 至 0.02)为免疫原性的负性预测因素。
核心结论
- 在 COVIAAD 中,Moderna Spikevax 基础免疫系列是安全的。
- MMF、RA 年龄>65 岁和利妥昔单抗与疫苗诱导的保护降低相关。
研究设计与样本
- 为期 12 个月的前瞻性、非随机、开放标签、对照试验,纳入稳定治疗的 RA(n=131)、接受 MMF 的 SLE(n=23)、泼尼松≥10 mg/日的其他风湿病(n=8)患者及年龄/性别匹配的健康对照(HC,n=58)。
- 评估不良事件、体液免疫应答(抗 SARS-CoV-2 刺突蛋白及其受体结合域 IgG 阳性、中和抗体)、细胞应答(ELISpot)及 COVID-19 感染率。
主要发现
- 接种后主动报告的不良事件频率组间相似(HC 90%、RA 86%、SLE 90%);肌肉骨骼不良事件在 RA 中更常见(HC 48% vs RA 66%,Δ95%CI 3 至 32.6)。
- 接种后疾病活动度评分未升高,未报告疫苗相关严重不良事件。
- 接种后免疫原性在 RA 和 SLE 中降低(RA 90.2%、SLE 86.4%;两者与 HC 比较的 ΔCI 均排除无效值)。
- 中和抗体在患者中降低(RA 82.6%、SLE 81.8%)。
- RA 中年龄>65 岁(OR 0.3,95%CI 0.1 至 0.8)和利妥昔单抗治疗(OR 0.003,95%CI 0.001 至 0.02)为免疫原性的负性预测因素;ELISpot 在 16/52 例受检 RA 和 17/26 例 HC 中阳性(ΔCI 11.2-53.3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease. METHODS: We conducted a 12-month, prospective, non-randomised, open-label, comparative trial of adults with either rheumatoid arthritis (RA, n=131) on stable treatment; systemic lupus erythematosus (SLE, n=23) on mycophenolate mofetil (MMF); other rheumatic diseases on prednisone ≥10 mg/day (n=8) or age-matched/sex-matched controls (healthy control, HC, n=58). Adverse events (AEs), humoral immune responses (immunogenicity: IgG positivity for anti-SARS-CoV-2 spike protein and its receptor binding domain, neutralising antibodies (NAbs)), cellular responses (ELISpot) and COVID-19 infection rates were assessed. RESULTS: Frequency of solicited self-reported AEs following vaccination was similar across groups (HC 90%, RA 86%, SLE 90%); among them, musculoskeletal AEs were more frequent in RA (HC 48% vs RA 66% (Δ95% CI CI 3 to 32.6)). Disease activity scores did not increase postvaccination. No vaccine-related serious AEs were reported. Postvaccination immunogenicity was reduced in RA and SLE (RA 90.2%, SLE 86.4%; for both, ΔCIs compared with HC excluded the null). Similarly, NAbs were reduced among patients (RA 82.6%, SLE 81.8%). In RA, age >65 (OR 0.3, 95% CI 0.1 to 0.8) and rituximab treatment (OR 0.003, 95% CI 0.001 to 0.02) were negative predictors of immunogenicity. ELISpot was positive in 16/52 tested RA and 17/26 HC (ΔCI 11.2-53.3). During the study, 11 HC, 19 RA and 3 SLE patients self-reported COVID-infection. CONCLUSION: In COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases, the Moderna Spikevax primary series was safe. MMF, RA age >65 and rituximab were associated with reduced vaccine-induced protection.
引用
- Colmegna I, Valerio V, Amiable N, et al. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series. RMD Open. 2023. PMID: 38030231. doi:10.1136/rmdopen-2023-003400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。